Principal Investigator:
Michel Savard
CRIM
Project of $323,390 over 18 months
- Supported by CQDM through:
Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE) - And by a co-funding partner:
- Sorintellis Group
Challenge
Among the challenges facing the pharmaceutical industry are high attrition rates and the need to assess the success of clinical trials in the light of the risk factors inherent in the drug development process. In fact, less than 10% of potential drugs entering Phase 1 trials will ever reach the market. These risk factors contribute to failures in the later phases of clinical development, and it would be beneficial to detect them as early as possible to enable the various stakeholders to make the decisions necessary to prevent failure.
Solution
Sorintellis, in collaboration with Vantage Biotrials and the Computer Research Institute of Montreal (CRIM), previously developed a proof of concept for a priori estimation of clinical trial success. As part of this project, the research team is pursuing the development of a predictive risk assessment and analysis platform for the conduct of clinical trials, drawing on its expertise in the development of artificial intelligence (AI) solutions. This platform will be integrated into a large database developed by Sorintellis and will be based on a rigorous development protocol enabling the development of an innovative prescriptive approach that goes beyond the “black box” nature of many machine learning approaches, thus providing an indispensable tool for strategic decision-making.
Achievements/Impact
Through this collaborative research project, Sorintellis and the CRIM research team aim to offer pharmaceutical companies and contract research organizations cutting-edge technology to support complex decision-making processes in the planning and efficient conduct of clinical trials. In terms of AI innovation, the approaches evaluated will enable several interpretability techniques to be assessed, facilitating the development of trusted AI systems in new fields. For Quebec, this is an opportunity to develop cutting-edge technology that will energize the pharmaceutical industry and reinforce our global leadership in the conduct of clinical trials, while leveraging the strength of our AI ecosystem.
